

Date 15/12/2025  
Your Ref  
Our Ref 10858

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION – PRESCRIBING

I write in response to your request for information in relation to prescribing.

Question:

- How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available?

Answer:

Name of medicine	Number patients treated
1.1 Acalabrutinib (Calquence)	18
1.2 Ibrutinib (Imbruvica)	31
1.3 Pirtobrutinib (Jaypirca)	Nil
1.4 Venetoclax (Venclyxto)	38
1.5 Zanubrutinib (Brukinsa)	27
1.6 Rituximab	Information Unavailable
1.7 Obinutuzumab (Gazyvaro)	Information Unavailable

Question:

- How many patients with **Chronic Lymphocytic Leukaemia** OR **Small B-Cell Lymphoma** – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available?

Answer:

Name of medicine	Number patients treated
2.1 Acalabrutinib (Calquence)	29
2.2 Ibrutinib (Imbruvica)	22
2.3 Pirtobrutinib (Jaypirca)	Nil
2.4 Venetoclax (Venclyxto)	27
2.5 Zanubrutinib (Brukinsa)	5<

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common name of Lothian Health Board*

2.6 Obinutuzumab (Gazyvaro)	10
2.7 Rituximab	5<
2.8 Bendamustine	5<
2.9 Chlorambucil	Nil
2.10 Fludarabine	Nil
2.11 Cyclophosphamide	Nil

Question:

3. How many patients with **Chronic Lymphocytic Leukaemia** OR **Small B-Cell Lymphoma** were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available?

Answer:

Name of monotherapy or combination	Number patients treated
3.1 Ibrutinib + venetoclax	Nil
3.2 Obinutuzumab + venetoclax	9
3.3 Zanubrutinib monotherapy / maintenance	5<
3.4 Ibrutinib monotherapy / maintenance	22
3.5 Venetoclax monotherapy	20
3.6 Venetoclax + rituximab	5<
3.7 Rituximab monotherapy	Nil
3.8 Ibrutinib + Bendamustine + Rituximab	Nil

Question:

4. How many patients with **Mantle Cell Lymphoma** (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available?

Answer:

Name of monotherapy or combination	Number patients treated
4.1 Acalabrutinib	Nil
4.2 Ibrutinib	5<
4.3 Zanubrutinib	5<
4.4 Ibrutinib + R-CHOP / R-DHAP	Nil
4.5 Pirtobrutinib	Nil

Question:

5. How many patients with **Acute Myeloid Leukaemia** – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available?

Answer:

Name of medicine	Number patients treated
5.1 Azacitidine	20
5.2 Cytarabine	5<
5.3 Venetoclax (Venclyxto)	11

Question:

6. How many patients with **Acute Myeloid Leukaemia** were treated with the following medicines in combination, in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available?

Answer:

Name of combination	Number patients treated
6.1 Venetoclax + Azacitidine ( <i>with or without posaconazole</i> )	11
6.2 Venetoclax + Cytarabine ( <i>inc. V + LDAC, V + ARAC, V+ ARA-C</i> )	Nil

Question:

7. How many patients with **Multiple Myeloma** were treated with the following medicines in combination, in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available?

Answer:

Name of medicine	Number patients treated
7.1 Daratumumab + Bortezomib + Dexamethasone [DVd]	26
7.2 Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd]	5<
7.3 Daratumumab + Lenalidomide + Dexamethasone [DRD]	51
7.4 Lenalidomide + Dexamethasone [Rd]	57
7.5 Lenalidomide (maintenance monotherapy)	57
7.6 Carfilzomib + Dexamethasone [Kd]	7
7.7 Belantamab mafodotin (monotherapy)	Nil
7.8 Belantamab mafodotin + Bortezomib + Dexamethasone [BVd]	Nil
7.9 Daratumumab (monotherapy)	19
7.10 Isatuximab + Bortezomib + Lenalidomide + Dexamethasone [IsaVRd]	Nil
7.11 Isatuximab + Pomalidomide + Dexamethasone [IsaPd]	9

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records,

the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive